Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy

被引:13
|
作者
Mucha, Olga [1 ]
Podkalicka, Paulina [1 ]
Kazirod, Katarzyna [1 ]
Samborowska, Emilia [2 ]
Dulak, Jozef [1 ]
Loboda, Agnieszka [1 ]
机构
[1] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Gronostajowa 7, PL-30387 Krakow, Poland
[2] Polish Acad Sci, Inst Biochem & Biophys, Mass Spectrometry Lab, Warsaw, Poland
关键词
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; Simvastatin; DMD; Duchenne muscular dystrophy; Angiogenesis; mdx; SKELETAL-MUSCLE; HEME OXYGENASE-1; SATELLITE CELLS; STATIN THERAPY; NITRIC-OXIDE; MYOPATHY; EXPRESSION; OSTEOPONTIN; INHIBITION; BIOMARKERS;
D O I
10.1186/s13395-021-00276-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background Duchenne muscular dystrophy (DMD) is an incurable disease, caused by the mutations in the DMD gene, encoding dystrophin, an actin-binding cytoskeletal protein. Lack of functional dystrophin results in muscle weakness, degeneration, and as an outcome cardiac and respiratory failure. As there is still no cure for affected individuals, the pharmacological compounds with the potential to treat or at least attenuate the symptoms of the disease are under constant evaluation. The pleiotropic agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, have been suggested to exert beneficial effects in the mouse model of DMD. On the other hand, they were also reported to induce skeletal-muscle myopathy. Therefore, we decided to verify the hypothesis that simvastatin may be considered a potential therapeutic agent in DMD. Methods Several methods including functional assessment of muscle function via grip strength measurement, treadmill test, and single-muscle force estimation, enzymatic assays, histological analysis of muscle damage, gene expression evaluation, and immunofluorescence staining were conducted to study simvastatin-related alterations in the mdx mouse model of DMD. Results In our study, simvastatin treatment of mdx mice did not result in improved running performance, grip strength, or specific force of the single muscle. Creatine kinase and lactate dehydrogenase activity, markers of muscle injury, were also unaffected by simvastatin delivery in mdx mice. Furthermore, no significant changes in inflammation, fibrosis, and angiogenesis were noted. Despite the decreased percentage of centrally nucleated myofibers in gastrocnemius muscle after simvastatin delivery, no changes were noticed in other regeneration-related parameters. Of note, even an increased rate of necrosis was found in simvastatin-treated mdx mice. Conclusion In conclusion, our study revealed that simvastatin does not ameliorate DMD pathology.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy
    Olga Mucha
    Paulina Podkalicka
    Katarzyna Kaziród
    Emilia Samborowska
    Józef Dulak
    Agnieszka Łoboda
    [J]. Skeletal Muscle, 11
  • [2] A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
    Verhaart, Ingrid E. C.
    van de Vijver, Davy
    Boertje-van der Meulen, Joke W.
    Putker, Kayleigh
    Adamzek, Kevin
    Aartsma-Rus, Annemieke
    van Putten, Maaike
    [J]. PLOS ONE, 2019, 14 (04):
  • [3] Sildenafil Ameliorates Skeletal Muscle Pathology in the mdx Mouse Model of Duchenne Muscular Dystrophy
    Percival, Justin
    Whitehead, Nicholas
    Siegel, Michael
    Gray, Heidi
    Adamo, Candace
    Marcinek, David
    Beavo, Joseph
    Froehner, Stanley
    [J]. FASEB JOURNAL, 2011, 25
  • [4] Respiratory Pathology in a Humanized Mouse Model of Duchenne Muscular Dystrophy
    McCall, Angela
    Bailey, Aidan
    Pucci, Logan
    Dhindsa, Justin
    Robinson-Hamm, Jacqueline
    Gersbach, Charles
    ElMallah, Mai
    [J]. FASEB JOURNAL, 2021, 35
  • [5] Effect of treatment with grow factors on muscle pathology in the mdx mouse model of Duchenne muscular dystrophy
    Nielsen, T.
    Pinos, T.
    Krag, T.
    Vissing, J.
    [J]. NEUROMUSCULAR DISORDERS, 2015, 25 : S291 - S291
  • [6] Eosinophils Do Not Drive Acute Muscle Pathology in the mdx Mouse Model of Duchenne Muscular Dystrophy
    Sek, Albert C.
    Moore, Ian N.
    Smelkinson, Margery G.
    Pak, Katherine
    Minai, Mahnaz
    Smith, Roberta
    Ma, Michelle
    Percopo, Caroline M.
    Rosenberg, Helene F.
    [J]. JOURNAL OF IMMUNOLOGY, 2019, 203 (02): : 476 - 484
  • [7] Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020
    Whitehead, N. P.
    Kim, M. J.
    Bible, K. L.
    Adams, M. E.
    Froehner, S. C.
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (05) : 865 - 866
  • [8] Resveratrol Ameliorates Muscular Pathology in the Dystrophic mdx Mouse, a Model for Duchenne Muscular Dystrophy
    Hori, Yusuke S.
    Kuno, Atsushi
    Hosoda, Ryusuke
    Tanno, Masaya
    Miura, Tetsuji
    Shimamoto, Kazuaki
    Horio, Yoshiyuki
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (03): : 784 - 794
  • [9] Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy
    Milad, Nadia
    White, Zoe
    Tehrani, Arash Y.
    Sellers, Stephanie
    Rossi, Fabio M. V.
    Bernatchez, Pascal
    [J]. SKELETAL MUSCLE, 2017, 7
  • [10] Reduced Sarcolemmal Membrane Repair Exacerbates Striated Muscle Pathology in a Mouse Model of Duchenne Muscular Dystrophy
    Paleo, Brian J.
    McElhanon, Kevin E.
    Bulgart, Hannah R.
    Banford, Kassidy K.
    Beck, Eric X.
    Sattler, Kristina M.
    Goines, Briana N.
    Ratcliff, Shelby L.
    Crowe, Kelly E.
    Weisleder, Noah
    [J]. CELLS, 2022, 11 (09)